```html

Zollinger‑Ellison Disease (Familial)

Overview

Zollinger‑Ellison disease (ZED) is a rare condition in which one or more gastrin‑secreting tumors (gastrinomas) develop in the pancreas or duodenum. The excess gastrin causes the stomach to produce large amounts of acid, leading to severe peptic ulcer disease, diarrhea, and malabsorption. When these tumors run in families they are termed familial gastrinoma syndrome, a hereditary form of ZED that accounts for roughly 5–10 % of all Zollinger‑Ellison cases. The disease is inherited in an autosomal dominant pattern, meaning a single mutated copy of the gene is enough to increase risk.

Who it affects:

• Men and women equally.
• Typically presents between the ages of 30–50, but familial cases can appear earlier.
• Estimated prevalence of all ZED is 0.5–2 cases per million people worldwide; familial cases are proportionally rarer.

Symptoms

Symptoms result from hyperacidic stomach secretions and the tumor’s local effects. They may develop gradually.

• Recurrent abdominal pain – often described as burning, worse when the stomach is empty.
• Peptic ulcers – multiple, large, or ulcerations that fail to heal despite standard therapy.
• Diarrhea – watery, sometimes steatorrhea (fatty stools) due to acid‑induced inactivation of pancreatic enzymes.
• Heartburn / gastro‑esophageal reflux disease (GERD) – chronic acid reflux.
• Nausea & vomiting – can be triggered by ulcer pain or gastric outlet obstruction.
• Weight loss – from malabsorption and reduced appetite.
• Gastrointestinal bleeding – melena or hematemesis from ulcer erosion.
• Fatigue & anemia – chronic blood loss or iron deficiency.
• Kidney stones – hypercalciuria may accompany the disease in some families.
• Pancreatic insufficiency symptoms – abdominal cramping, bloating, and foul‑smelling stools when the tumor suppresses pancreatic enzyme activity.

In familial ZED, multiple family members may experience similar symptom patterns, often prompting earlier medical evaluation.

Causes and Risk Factors

Genetic basis

The hereditary form is most commonly linked to mutations in the MEN1 gene (multiple endocrine neoplasia type 1). MEN1 encodes the protein menin, a tumor suppressor. Loss‑of‑function mutations lead to unchecked cell growth in the duodenum, pancreas, and other endocrine tissues. Less frequently, mutations in the APC or CDKN1B genes have been reported.

Other risk factors

• Family history: A first‑degree relative with ZED or MEN1 markedly raises risk.
• Age: Although hereditary, penetrance increases with age; most carriers develop disease by their 40s.
• Gender: No strong gender predilection, but some studies suggest slightly earlier presentation in males.
• Associated endocrine tumors: Patients with other MEN1 manifestations (parathyroid adenomas, pituitary adenomas) often have concurrent gastrinomas.

Diagnosis

Because symptoms overlap with common ulcer disease, a high index of suspicion is needed, especially when ulcers are refractory or multiple.

Laboratory tests

• Fasting serum gastrin level: Values > 1,000 pg/mL are highly suggestive, but levels may be modestly elevated in chronic proton‑pump inhibitor (PPI) use or renal failure.
• Secretin stimulation test: Administration of secretin paradoxically raises gastrin in ZED (positive if gastrin rises > 120 pg/mL).
• Chromogranin A: A marker of neuroendocrine tumors; helpful for monitoring.

Imaging studies

• Endoscopic ultrasound (EUS): Highly sensitive for locating small duodenal or pancreatic gastrinomas.
• Multiphasic contrast‑enhanced CT or MRI: Detects larger lesions and assesses metastatic spread.
• Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT: The most sensitive for neuroendocrine tumor localization and staging.

Genetic testing

If a familial pattern is suspected, sequencing of the MEN1 gene (and optionally APC, CDKN1B) is recommended. Testing enables cascade screening of relatives.[1] National Institutes of Health (NIH), 2022

Diagnostic criteria (summary)

1. Fasting gastrin > 1,000 pg/mL OR positive secretin test.
2. Imaging confirming a gastrinoma (≥ 0.5 cm) in pancreas/duodenum.
3. Exclusion of other causes of hypergastrinemia (e.g., chronic PPI use, atrophic gastritis).
4. Genetic confirmation of MEN1 mutation for the familial form.

Treatment Options

Treatment aims to control acid hypersecretion, remove or control tumor growth, and manage associated endocrine abnormalities.

Medical management

• Proton‑pump inhibitors (PPIs): High‑dose omeprazole, esomeprazole, or pantoprazole are first‑line to neutralize gastric acid. Doses often exceed standard ulcer therapy (e.g., omeprazole 80 mg daily).[2] Mayo Clinic, 2023
• Histamine‑2 receptor antagonists (H2 blockers): May be added for breakthrough symptoms, but PPIs remain superior.
• Somatostatin analogues (octreotide, lanreotide): Inhibit gastrin release and may shrink tumor size, especially in unresectable or metastatic disease.
• Chemotherapy / targeted therapy: For metastatic gastrinomas, regimens such as streptozocin‑based therapy, temozolomide, or everolimus (mTOR inhibitor) are used under oncology supervision.

Surgical options

• Enucleation or local excision: Preferred for solitary, well‑localized tumors <1 cm without metastasis.
• Pancreaticoduodenectomy (Whipple procedure): Considered for larger, infiltrative pancreatic gastrinomas.
• Distal pancreatectomy or duodenal resection: Tailored to tumor location.
• Cytoreductive surgery: May be performed when metastatic disease is limited to the liver.

In the familial context, surgeons often screen the entire pancreas and duodenum during the initial operation because multiple microscopic gastrinomas are common.

Lifestyle and supportive measures

• Eat small, low‑fat meals; avoid caffeine, alcohol, chocolate, and spicy foods that increase acid production.
• Maintain adequate hydration; replace electrolytes if chronic diarrhea is present.
• Supplement fat‑soluble vitamins (A, D, E, K) and calcium if malabsorption is documented.
• Regular bone density testing for those on long‑term PPIs or with MEN1‑related hyperparathyroidism.

Living with Zollinger‑Ellison Disease (Familial)

Monitoring & follow‑up

• Quarterly serum gastrin levels while on high‑dose PPIs; adjust dose based on symptom control and gastrin trends.
• Annual imaging (EUS, MRI, or ^68Ga‑DOTATATE PET/CT) to detect new or recurrent tumors.
• Genetic counseling for patients and at‑risk relatives; offer cascade testing to first‑degree family members.
• Screen for other MEN1 tumors: serum calcium & PTH annually, pituitary hormone panel if symptoms arise.

Practical daily tips

1. Medication adherence: Take PPIs 30 minutes before breakfast and dinner; never skip doses.
2. Meal timing: Space meals 3–4 hours apart; include a protein source at each meal to slow gastric emptying.
3. Diarrhea control: Use over‑the‑counter loperamide as directed; consider pancreatic enzyme replacement if steatorrhea persists.
4. Stress management: Stress can exacerbate acid secretion – practice mindfulness, yoga, or gentle exercise.
5. Travel preparedness: Carry a spare supply of PPIs, a letter from your physician, and a list of local hospitals in case of an acute ulcer bleed.

Psychosocial aspects

Living with a hereditary cancer syndrome can be emotionally taxing. Support groups (e.g., MEN1 Foundations, rare disease forums) and mental‑health counseling are recommended.[3] Cleveland Clinic, 2022

Prevention

Because the disease is genetic, primary prevention is not possible, but several measures can reduce disease impact and improve outcomes:

• Early genetic testing: Identify carriers before symptoms develop; initiate surveillance at age 10–12 for MEN1 families.
• Avoid chronic PPI use before diagnosis: Long‑term acid suppression can mask gastrin elevations; discuss any medication use with your doctor.
• Healthy lifestyle: Smoking cessation and limiting alcohol reduce ulcer risk and may slow tumor growth.
• Vaccinations: For patients on immunosuppressive therapy (e.g., everolimus), stay up‑to‑date with influenza, pneumococcal, and COVID‑19 vaccines.

Complications

If untreated or poorly controlled, ZED can lead to serious, life‑threatening problems:

• Perforated peptic ulcer → peritonitis and emergent surgery.
• Massive gastrointestinal bleeding → anemia, transfusion dependence.
• Severe malnutrition due to chronic diarrhea and fat malabsorption.
• Metastatic gastrinoma – commonly spreads to regional lymph nodes, liver, and occasionally bone.
• Electrolyte disturbances – hypokalemia, metabolic alkalosis from chronic diarrhea.
• Osteoporosis – from chronic acid load, PPI use, and MEN1‑related hyperparathyroidism.
• Secondary infections – especially in patients receiving somatostatin analogues or chemotherapy.

When to Seek Emergency Care

---

References

1. National Institutes of Health (NIH). MEN1 Clinical Overview. 2022. https://www.nih.gov
2. Mayo Clinic. Zollinger‑Ellison Syndrome Treatment. Updated 2023. https://www.mayoclinic.org
3. Cleveland Clinic. Living With MEN1 and Associated Tumors. 2022. https://my.clevelandclinic.org
4. World Health Organization (WHO). Gastric Neuroendocrine Tumors: Classification and Management. 2021.
5. American Cancer Society. Neuroendocrine Tumors of the Pancreas. 2024.

```